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PURPOSE. To compare estrogen (ER), progesterone (PR), and human epidermal growth factor-2
(HER2) receptor expression in the primary tumor of patients affected by choroidal metastases
from breast carcinoma (BC) versus those with extraocular metastases.
METHODS. Eighteen consecutive patients affected by choroidal metastases from BC were
included. We defined ER, PR, and HER2 positivity of the primary tumor following standard
guidelines. Breast carcinoma molecular subtypes were also identified (luminal A, luminal B,
HER2-enriched, and triple negative). Forty consecutive patients affected by metastatic BC
without choroidal involvement were included as a control group.
RESULTS. The study group and the control group were similar for age, sex, race,
histopathologic classification of the primary tumor (ductal, lobular, others), and American
Joint Committee on Cancer Tumor–Node–Metastasis stage at the time of primary tumor
diagnosis (P > 0.05). Patients affected by choroidal metastases from BC showed a significantly
higher expression of ER (P ¼ 0.009) and PR (P ¼ 0.018) receptors in the primary tumor
compared with nonchoroidal metastatic BC. Across all patients, the luminal B molecular
subtype was related to the presence of choroidal involvement (P ¼ 0.003). Considering
luminal tumors only, the luminal B subclassification was also related to the presence of
choroidal involvement (P ¼ 0.009).
CONCLUSIONS. Choroidal metastases from BC are associated with ER and PR expression in the
primary tumor and the luminal B molecular subtype.
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Uveal metastasis is the most common intraocular malignancyin the adult population, with a prevalence of 4% to 10%
among carcinoma patients. The primary malignancy is usually
located in the breast (47%) or in the lung (21%), and the
choroid is the most common site of uveal metastases.1–6 Most
patients with choroidal metastases have already been diagnosed
with systemic cancer at the time of eye tumor diagnosis, and
choroidal metastases are generally associated with disseminated
disease and poor prognosis.4 Nevertheless, in a consistent
proportion (30%) of patients with choroidal metastases, the
diagnosis of an intraocular secondary lesion precedes the
diagnosis of the primary tumor.1–6
About 1 in 8 women (12%) in the United States develop
invasive breast carcinoma (BC) over the course of a lifetime. At
present, BC is the most frequently diagnosed cancer with an
increasing incidence worldwide and it is the leading cause of
cancer-related deaths in women.7 Metastatic disease is reported
to develop in up to 30% of node-negative (early stage) BC
patients at diagnosis and in an even larger fraction of node-
positive disease patients.8
Reliable, inexpensive tumor markers such as estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor-2 (HER2) allowed the
identification of the ER/PR/HER2 subtypes of BC, which is
the basis for current BC classification, prognostication, and
therapy.9 Different subtypes of BC based on the ER/PR/HER2
classification have shown to have preferential site of metasta-
ses, adding increasing evidence of a complex, nonrandom
pattern of distant metastatic spread in BC.8–10 The aim of the
present study was to analyze the ER, PR, and HER2 receptor
expression in the primary tumor of patients affected by
choroidal metastases from BC, and to compare these data with
a control population composed of metastatic BC patients
without choroidal involvement.
PATIENTS AND METHODS
This was a retrospective observational case series with
prospective enrollment, compliant with the tenets of the
Declaration of Helsinki. The collaborative prospective ocular
oncology database maintained at our ocular oncology unit was
queried under institutional review board approval and
informed consent was obtained from the subjects after
explanation of the nature and possible consequences of the
study. Patients were recruited from those referred between
October 2011 and April 2016 to the ocular oncology service.
Informed consent was obtained from each patient. Inclusion
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criteria were: patients aged 21 years or older and affected by
choroidal metastases from histologically proven BC. Exclusion
criteria were: lack of full original documentation of the primary
tumor, including: the original histopathology classification
(ductal, lobular, others); the tumor stage at diagnosis (Amer-
ican Joint Committee on Cancer Tumor–Node–Metastasis
[AJCC-TNM])10; the receptor status (ER, PR, and HER2) of
the primary tumor drawn from the formal histopathologic
report and defined following standard guidelines.11–13 Briefly,
receptor positivity (þ) was defined as any positive nuclear
staining (i.e., greater than or equal to 1%) for ER and PR and an
immunohistochemistry score of 3þ or immunohistochemistry
score of 2þ plus fluorescent in situ hybridization with
amplification ratio ‡2.0 for HER2 (Figure). Intrinsic breast
cancer subtypes were determined according to criteria
recently recommended by the St. Gallen International Breast
Cancer Conference. The following definitions were used:
luminal A (ER and/or PR positive, HER2 negative, Ki67 inferior
to 14%); luminal B (ER and/or PR positive, Ki67 ‡14%, and/or
HER2 positive); HER2-enriched (ER and PR negative, HER2
positive, and any Ki67); and triple negative (ER and PR
negative, HER2 negative, and any Ki67).13
All patients underwent full ophthalmic examination at
baseline, including color fundus photography, A/B-scan ultra-
sonography (US), and spectral-domain optical coherence
tomography (SD-OCT) using a commercial device (Spectralis;
Heidelberg Engineering, Heidelberg, Germany). The clinical
diagnosis of choroidal metastasis from breast carcinoma was
confirmed in each case by a single experienced ocular
oncologist.
Forty consecutive patients affected by metastatic BC
without choroidal involvement, referred to our clinic for
routine ophthalmologic procedures (such as outpatient diag-
nostic procedures or treatments), were also enrolled as a
control group. The absence of choroidal involvement was
confirmed in each case by the same experienced ocular
oncologist.
The statistical analysis was carried out according to the
usual methods of descriptive statistics: frequency distribution
and percentages. Demographic and clinical data were also
described in terms of mean, standard deviation, and range
(minimum-maximum). Categorical variables were compared
using the v2 test or Fisher’s exact test, as appropriate;
continuous variables were compared using the Student’s t-test
or the Wilcoxon Mann-Whitney test as appropriate. All
analyses were performed using statistical software (SAS,
version 9.3; SAS Institute, Cary, NC, USA).
RESULTS
Eighteen consecutive patients affected by choroidal metastasis
from histologically proven BC were included (mean age, 54.1
6 11.1 years; range, 38–84). Seventeen patients were female
(94.4%) and a single patient was male (5.6%). Uveal metastases
were unifocal in 8 (44.4%) and multifocal in 10 (56.6%), with
unilateral involvement in 12 patients (66.7%) and bilateral
involvement in 6 patients (33.3%). Ultrasound examination
revealed a medium internal reflectivity with irregular structure
in 15 cases (83.3%). Perilesional serous retinal detachment was
detectable by US in 9 cases (50.0%) and in 18 cases (100%) by
SD-OCT. Anterior compression/obliteration of the overlying
choriocapillaris and an irregular (lumpy-bumpy) anterior
contour was also detected by SD-OCT in 12 (66.7%) and 14
tumors (77.8%), respectively. All uveal metastases were
choroidal in location. By histopathologic classification, the
primary tumor was invasive ductal carcinoma in 16 cases
(88.9%) and invasive lobular carcinoma in 2 cases (11.1%). At
the time of primary tumor diagnosis, AJCC-TNM classification
was stage I in five patients (27.8%), stage II in seven patients
(38.9%), stage III in four patients (22.2%), and stage IV in two
patients (11.1%).
The study group and the control group were similar in age,
sex, race, histopathologic classification of the primary tumor
(ductal, lobular, others) and AJCC-TNM stage at the time of
primary tumor diagnosis (P > 0.05; Table).10
Patients affected by choroidal metastases from BC were
characterized as ERþ in 18 cases (100%), PRþ in 16 cases
(88.8%), and HER2þ in 3 cases (16.7%). Patients affected by
metastatic BC without choroidal involvement were character-
ized by ERþ in 28 cases (70%), PRþ in 23 cases (57.5%), and
HER2þ in 8 cases (20%). Patients affected by choroidal
metastases of BC showed a statistically significant higher
expression of ER (P¼0.009) and PR (P¼0.018) receptor in the
primary tumor compared with nonchoroidal metastatic BC.
Following the St. Gallen International Breast Cancer
Conference surrogate definition of intrinsic subtypes of BC,
all patients (100%) affected by choroidal metastases of BC had
luminal tumors. Of these, 5 patients were affected by luminal A
(27.8%) and 13 by luminal B (72.2%) BC. No patients were
affected by HER2-enriched or triple negative BC molecular
subtypes. In the control group, 23 patients (57.5%) were
affected by luminal A, 12 by luminal B (30%), 2 patients (5%) by
HER2-enriched, and 3 patients (7.5%) by triple negative BC
molecular subtypes. Considering all patients, the luminal B
molecular subtype was associated with choroidal involvement
(P ¼ 0.003). Considering luminal tumors only, the subclassifi-
cation in luminal B was also associated with choroidal
involvement (P ¼ 0.009).
DISCUSSION
Uveal metastasis from carcinoma represents an increasing
problem in the context of an aging population and enhanced
survival of stage IV cancer patients.1–4 These lesions may
progress rapidly and are potentially sight-threatening.4 Early
diagnosis and appropriate timely treatment are therefore
mandatory to maintain patients’ quality of life. External beam
radiotherapy (EBRT), chemotherapy, hormone and biologic
therapies, brachytherapy, and photodynamic therapy are the
main therapeutic modalities for the management of these
lesions, with the strongest evidence supporting timely EBRT
FIGURE. Immunohistochemic analysis of ER, PR, and HER2 expression
in the primary tumor of patients enrolled in our tumor cohort.
Representative positive (þ) and negative (–) immunostaining for ER,
PR, and HER2 expression (320 magnification).
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(grade B; strong support for recommendation).14 Nevertheless,
alternative or adjuvant therapies, such as systemic chemother-
apy and hormone therapies for choroidal metastases from BC,
are recently emerging.3,6,15,16 Demirci et al.6 reported a local
tumor control rate of 81% using systemic chemotherapy or
hormone therapy in affected patients. Thus, a more deep
knowledge of the ER/PR/HER2 receptor status of patients with
choroidal metastatic involvement by BC could potentially
influence the treatment of these patients.
Major BC intrinsic molecular subtypes are defined by the
expression of hormone receptors and HER2, with or without
an accompanying Ki-67 proliferation index. The resulting
regulation of different signalling pathways and gene expression
profiles influences the distinct biologic behavior of these
tumor subtypes, including aggressiveness and organ-specific
metastatic potential.17–20
Expression of ER and PR receptors by choroidal metastases
of BC and the consequently good response to hormonal
therapy have been previously reported in single case
reports.3,15,16 Nevertheless, no work focusing on the ER, PR,
and HER2 receptor expression in the primary tumor of patients
affected by choroidal metastases of BC has been published, nor
have there been any reports investigating the intraocular
specific metastatic potential of different BC molecular sub-
types.
In our prospectively collected series, all patients with
choroidal metastases of BC showed ER positivity and, in a high
percentage of them, also PR positivity. Moreover, combining
the receptor status of patients affected by choroidal metastases
by BC, 76% of these patients have a primary tumor classified as
luminal B. Compared with population-based studies, the
luminal B phenotype is expected to be present in a much
lower proportion (20% to 30% of BC overall).9,13 This
difference is highlighted also by the luminal B percentage of
our control group (30%).9,13,17 The presence of receptor
positivity in each primary BC with choroidal metastases is of
clinical importance, both from biologic and therapeutic
perspectives.
Luminal tumors have cells resembling those of tumors
starting in the inner (luminal) cells lining the mammary ducts.
Patients with luminal B tumors are diagnosed at a younger age
than those with luminal A tumors. Compared with luminal A
tumors, luminal B tumors tend to have factors that lead to a
relatively poorer prognosis, including higher tumor grade,
larger tumor size, and lymph node positivity at diagnosis.10,20
Some (about 30%) luminal B tumors contain p53 gene
mutations. Women with luminal B tumors, compared with
HER2-enriched and triple negative tumors, tend to have fairly
high survival rates, although not as high as those with luminal
A tumors.10,20
Among all BC molecular subtypes, the skeleton was the
most common site of metastatic disease, representing approx-
imately half (48%) of patients, followed by liver (27%), lung
(23%), central nervous system (17%), and pleura (7%).20 Breast
cancer subtypes differ not only in primary tumor characteris-
tics, but also in their metastatic behavior. This fact could
potentially be used in determining the appropriate strategy for
patient follow-up. The luminal A and B subtypes are associated
with more bone metastases compared with the HER2-enriched
and triple negative BC.20 Furthermore, the luminal A subtype is
associated with bone only metastases. Liver metastases are
more frequently observed in HER2-enriched compared with
luminal A and triple negative BC, and the luminal subtypes are
less frequently associated with lung metastases compared with
triple negative BC.20 The luminal A subtype is also less
frequently associated with central nervous system metastases
than HER2-enriched and triple negative BC. Similarly, the
luminal B subtype is less frequently associated with central
nervous system metastases compared with the HER2-enriched,
TABLE. Clinical and Demographic Characteristics of Enrolled Patients
Study Group* Control Group† P Value All Patients
Patients, n 18 40 – 58
Age, y, mean (range) 54.1 6 11.1 (39–84) 55.9 6 10.7 (38–83) >0.05 55.2 6 11.2 (38–84)
Sex, female/male (%) 17/1 (94/6) 40/0 (100/0) >0.05 57/1 (98/2)
Race, Caucasian/other races (%) 17/1 (94/6) 38/2 (95/5) >0.05 55/3 (95/5)
Affected breast, right/left/both (%) 9/8/1 (50/44/6) 19/18/3 (47/45/7) >0.05 28/26/4 (48/45/7)
Primary tumor histology, ductal/lobular/others (%) 16/2/0 (89/11/0) 36/4/0 (90/10/0) >0.05 52/6/0 (90/10/0)
Affected eye, right/left/both (%) 7/5/6 (39/28/33) NA – NA
AJCC-TNM10 stage at the time of primary tumor diagnosis
Stage I, n (%) 5 (28) 14 (35) >0.05 19 (33)
Stage II, n (%) 7 (39) 15 (37) >0.05 22 (38)
Stage III, n (%) 4 (22) 6 (15) >0.05 10 (17)
Stage IV, n (%) 2 (11) 5 (13) >0.05 7 (12)
Receptor status (primary tumor)
ERþ, n (%) 18 (100) 28 (70) 0.009‡ 46 (79)
PRþ, n (%) 16 (89) 23 (57) 0.018‡ 39 (67)
HER2þ, n (%) 3 (17) 8 (20) >0.05 11 (19)
Molecular subtypes (primary tumor)
Luminal A, n (%) 5 (28) 23 (57) 0.036‡ 28 (48)
Luminal B, n (%) 13 (72) 12 (30) 0.003‡ 25 (43)
HER2-enriched, n (%) 0 (0) 2 (5) >0.05 2 (3)
Triple negative, n (%) 0 (0) 3 (7) >0.05 3 (5)
NA, not applicable.
* Patients affected by choroidal metastases from BC.
† Patients affected by metastatic BC without choroidal involvement.
‡ Statistically significant.
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showing a similar trend when compared with triple negative
BC.20
Soni et al.18 recently reported that luminal tumors are
remarkable for their significant bone-seeking phenotype and
are less frequently observed in lung, brain, and pleural
metastases, and less likely to be associated with multiorgan
relapse. Notably, these authors reported that there was no
significant difference between the luminal A and B subtypes for
any site of relapse.18 In the present study, a statistically
significant association of metastatic homing to the choroid was
observed for luminal B breast cancer, suggesting that this
particular subtype of BC may have the choroid as a preferential
homing. The mechanisms by which the luminal B breast
cancer tumors tend to metastasize to the choroid remain to be
elucidated. Thus, further investigations into the molecular
mechanisms of this relationship are warranted.
The higher expression levels of ER and PR in the primary
tumor of patients affected by metastatic BC with choroidal
involvement raises the possibility that this knowledge could
potentially be used in determining the appropriate treatment
for these patients, such as the use of the aromatase inhibitors.
However, the major limitation of this study is that BC receptors
status was not analyzed directly in the intraocular lesion, but
only in the primary tumor. It would be certainly interesting to
know whether such increase in ER and PR expression is
maintained in the secondary lesion or whether the choroidal
metastases have different expression levels of these receptors,
possibly due to a different microenvironment compared with
the tissues surrounding the primary tumor. Unfortunately,
given that intraocular metastases are mostly treated by
conservative (nonsurgical) treatment, no material is available
to perform these analyses directly in the choroidal lesions.6
Moreover, at least in the standard clinical practice, patient
treatment is planned assuming, in absence of other direct
evidence, that both primary tumor and metastases have similar
receptors status.8
Another possible limitation of this study is that the primary
tumor of most of the enrolled patients was diagnosed in local
referral centers. Therefore, the specimens of the primary
tumors were not fully available for additional assays to confirm
the data obtained by standard immunohistochemistry. Lack of
standardization, technical variability in laboratory protocols,
and subjective interpretation are major problems associated
with immunohistochemistry; therefore, these results need
future confirmation by quantitative PCR or Western blot.
Choroidal metastases are often considered by nonophthal-
mologists as a group with other central nervous system
metastases, which are reported to have a greater incidence in
nonluminal BC.9 Our results underline that BC with choroidal
involvement is most often luminal B breast cancer, and thus
biologically different from those that preferentially metastasize
to the central nervous system. These findings hint that a clear
distinction has to be made, given the different histologic nature
of the choroid, which is primarily a vascular structure, from
nervous tissue, as well as the difference in expected molecular
BC subtypes homing to the choroid and the central nervous
system.
In conclusion, choroidal metastases by BC were associated
with ER and PR expression in the primary tumor and the
luminal B molecular subtype. Despite the small sample size of
our population, these results suggest that primary tumor
receptor expression and molecular subtype may influence the
choroidal metastatic tropism of BC. Characterization of BC
subtypes and their metastatic behavior could improve the
diagnostic and screening approach to patients affected by this
tumor. The identification of a specific BC molecular subtype
associated with choroidal involvement could also prevent the
worsening of debilitating vision-related symptoms with prompt
systemic treatment based on the expected sensitivity to
antihormone drugs.
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